MX2020001644A - Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes. - Google Patents
Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes.Info
- Publication number
- MX2020001644A MX2020001644A MX2020001644A MX2020001644A MX2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A
- Authority
- MX
- Mexico
- Prior art keywords
- senescent cells
- age
- conditions
- ophthalmic conditions
- glaucoma
- Prior art date
Links
- 206010012689 Diabetic retinopathy Diseases 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 230000007310 pathophysiology Effects 0.000 abstract 2
- 201000004569 Blindness Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940125381 senolytic agent Drugs 0.000 abstract 1
- 229940126586 small molecule drug Drugs 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se basa en el descubrimiento de que muchas afecciones oculares asociadas con el envejecimiento están mediadas, al menos en parte, por células que tienen un fenotipo senescente. Las células senescentes se acumulan con la edad y expresan factores que contribuyen a la fisiopatología de las afecciones relacionadas con la edad. Los datos muestran que en los pacientes de la misma edad, la gravedad de las afecciones relacionadas con la edad se correlaciona con la abundancia de células senescentes, y que la eliminación de las células senescentes puede ayudar a anular la afección. Como parte de esta invención, se proporcionan fármacos de molécula pequeña que eliminan células senescentes del tejido afectado en el ojo que tienen una eficacia especial en el tratamiento de afecciones oftálmicas. No solo inhiben la progresión de la enfermedad, sino que también pueden revertir parte de la fisiopatología, como la neovascularización y la obliteración de los vasos, que conducen a la pérdida de la visión. Estos agentes senolíticos tienen un perfil apropiado de dosis y especificidad para ser efectivos en el manejo clínico de afecciones oftálmicas previamente intratables.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/675,171 US20180000816A1 (en) | 2015-02-06 | 2017-08-11 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US201762579793P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/046553 WO2019033119A1 (en) | 2017-08-11 | 2018-08-13 | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001644A true MX2020001644A (es) | 2020-07-13 |
Family
ID=63254539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001644A MX2020001644A (es) | 2017-08-11 | 2018-08-13 | Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes. |
| MX2025004366A MX2025004366A (es) | 2017-08-11 | 2020-02-10 | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004366A MX2025004366A (es) | 2017-08-11 | 2020-02-10 | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4234025A3 (es) |
| JP (2) | JP7278257B2 (es) |
| CN (1) | CN111372598A (es) |
| AU (2) | AU2018314280B2 (es) |
| CA (1) | CA3072673A1 (es) |
| MX (2) | MX2020001644A (es) |
| WO (1) | WO2019033119A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CA3103740A1 (en) | 2018-06-29 | 2020-01-02 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| EP3840785A4 (en) * | 2018-08-20 | 2022-07-13 | Wuhan Neurophth Biotechnology Limited Company | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY |
| JP2022548071A (ja) * | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| CN114728006A (zh) * | 2020-05-04 | 2022-07-08 | 苏州亚盛药业有限公司 | 治疗冠状病毒感染的方法 |
| JP2024501033A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物 |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| WO2022221315A1 (en) * | 2021-04-13 | 2022-10-20 | Unity Biotechnology, Inc. | Methods of treating retinal vasculopathies |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2025009608A1 (ja) * | 2023-07-06 | 2025-01-09 | 学校法人自治医科大学 | 生体内物質又は薬物の生体内半閉鎖系における濃度調節剤 |
| CN119925379B (zh) * | 2025-03-05 | 2025-09-05 | 中南大学湘雅医院 | Bcl3抑制剂在制备治疗青光眼的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| EP2154406B1 (en) | 2001-04-11 | 2013-07-31 | Nippon Steel & Sumitomo Metal Corporation | Threaded joint for steel pipes and process for the surface treatment thereof |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
| AU2012209295B2 (en) * | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| WO2014113413A1 (en) * | 2013-01-16 | 2014-07-24 | The Regents Of The University Of Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
| RU2015149680A (ru) * | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w |
| US9737205B2 (en) | 2013-07-31 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for evaluating progression of age-related macular degeneration |
| US20150038140A1 (en) | 2013-07-31 | 2015-02-05 | Qualcomm Incorporated | Predictive mobility in cellular networks |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
-
2018
- 2018-08-13 EP EP23166363.4A patent/EP4234025A3/en active Pending
- 2018-08-13 CN CN201880063962.8A patent/CN111372598A/zh active Pending
- 2018-08-13 WO PCT/US2018/046553 patent/WO2019033119A1/en not_active Ceased
- 2018-08-13 EP EP18188799.3A patent/EP3441069B1/en active Active
- 2018-08-13 CA CA3072673A patent/CA3072673A1/en active Pending
- 2018-08-13 AU AU2018314280A patent/AU2018314280B2/en active Active
- 2018-08-13 JP JP2020507573A patent/JP7278257B2/ja active Active
- 2018-08-13 MX MX2020001644A patent/MX2020001644A/es unknown
-
2020
- 2020-02-10 MX MX2025004366A patent/MX2025004366A/es unknown
-
2023
- 2023-05-08 JP JP2023076763A patent/JP2023100864A/ja active Pending
- 2023-10-16 AU AU2023251388A patent/AU2023251388B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020109987A (ru) | 2021-09-13 |
| AU2023251388B2 (en) | 2024-12-12 |
| MX2025004366A (es) | 2025-05-02 |
| JP7278257B2 (ja) | 2023-05-19 |
| WO2019033119A1 (en) | 2019-02-14 |
| AU2018314280A1 (en) | 2020-02-27 |
| EP3441069B1 (en) | 2023-04-05 |
| EP4234025A2 (en) | 2023-08-30 |
| EP4234025A3 (en) | 2024-04-24 |
| JP2020530470A (ja) | 2020-10-22 |
| CA3072673A1 (en) | 2019-02-14 |
| EP3441069A1 (en) | 2019-02-13 |
| JP2023100864A (ja) | 2023-07-19 |
| CN111372598A (zh) | 2020-07-03 |
| AU2018314280B2 (en) | 2023-07-20 |
| AU2023251388A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025004366A (es) | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro | |
| Sloot et al. | Effective corneal collagen crosslinking in advanced cases of progressive keratoconus | |
| IL282624A (en) | Methods and compositions for the treatment of sight beard, mydriasis and other disorders of the eyes | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| Elbaz et al. | Accelerated versus standard corneal collagen crosslinking combined with same day phototherapeutic keratectomy and single intrastromal ring segment implantation for keratoconus | |
| PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| BR112019005586A2 (pt) | oligonucleotídeos antissensos para o tratamento de doença ocular | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| EA201301277A1 (ru) | Композиции и способы лечения заболеваний сетчатки | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| MX2016009331A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| WO2011139357A8 (en) | Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| WO2011137344A3 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
| MX2021007709A (es) | Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. | |
| NZ746468A (en) | Methods of treating ocular conditions | |
| Mahadevan et al. | Unique hard scleral lens post-LASIK ectasia fitting | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| Bleyen et al. | Not only hard contact lens wear but also soft contact lens wear may be associated with blepharoptosis | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras |